BioVU Archive — Page 4 of 8

May 19, 2022

Genetics and blood pressure

Including polygenic risk scores for blood pressure may improve predictive models to identify people at risk for treatment-resistant hypertension.

By Leigh MacMillan
May 19, 2022

A clue to an adverse drug event in children

Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.

By Joshua Baker
May 9, 2022

Gene variants and transplant drug dose

Genotyping multiple enzymes that metabolize the immunosuppressive drug tacrolimus — common used for lung transplant recipients — is important for correct dosing of the drug, Vanderbilt researchers found.

By Leigh MacMillan
May 5, 2022

Gene network linked to Type 2 diabetes

Vanderbilt researchers used a novel analytical approach to identify a network of genes associated with Type 2 diabetes, including 31 genes that had not previously been associated with the disease.

By Joshua Baker
April 26, 2022

Calculating risk for uterine fibroids

Vanderbilt researchers have constructed a polygenic risk score for uterine fibroids that will be useful for exploring causes of these benign tumors and identifying novel drug targets and therapies.

By Leigh MacMillan
VUMC’s new automated biobanking system can store as many as 10 million biospecimens.
April 6, 2022

Major grant renewal to provide five more years of support for VICTR

Vanderbilt University Medical Center has competed successfully for a third renewal of its Clinical and Translational Science Award by the National Institutes of Health.

By Bill Snyder